NovAliX Conference 2013 <br />Biophysics in Drug Discovery
Tuesday October 15, 2013
13:00Registration
14:00Social Programme
16:45Welcome Address
Chair
Dr Takaaki MIURA
(CHUGAI PHARMACEUTICAL, Kanagawa, Japan)
17:00KN01 - Biophysical Methods and Fragment Based Drug Discovery: Targeting Protein-Protein Interactions in Cell Regulatory Systems
Prof. Sir Tom BLUNDELL
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)
18:00Welcome Reception
Wednesday October 16, 2013
08:30Registration
1st Session - Biophysical Characterisation
Chair
Dr Johannes OTTL
(NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland)
09:00PL01 - Binding of Drug Substances to Molecular Targets Investigated by Biophysical Methods
Dr Michael HENNIG
(F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland)
09:40PL02 - Enabling GPCR Drug Discovery Through Structural and Biophysical Insights
Dr Rob COOKE
(HEPTARES, Hertfordshire, United Kingdom)
10:20Coffee Break
10:50OC01 - Biophysical Investigations of the Synergistic Activities of Antimicrobial Peptides: New Strategies to Fight Multiresistance
Prof. Burkhard BECHINGER
(UNIVERSITY OF STRASBOURG, Strasbourg, France)
11:15OC02 - X-Ray Crystallography, Kinetic Target-Guided Synthesis and NMR to Unravel the Mode of Action of Insulin Degrading Enzyme Modulators
Prof. Rebecca DEPREZ-POULAIN
(UNIVERSITY OF LILLE, Lille, France)
11:40PL03 - Biophysics to Drive Lead Discovery
Dr Matthias FRECH
(MERCK, Darmstadt, Germany)
12:20Lunch and Networking
2nd Session - Mechanistic Analysis
Chair
Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)
14:00PL04 - Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics: DOT1L and EPZ-5676
Dr Ann BORIACK-SJODIN
(EPIZYME, Cambridge, United States)
14:40PL05 - Investing in Knowledge: Combining Biophysical Data in Fragment-Based Drug Discovery
Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)
15:20OC03 - Residence and Recognition Time and their Use for Structure Kinetic Relationships and for Judging Efficacy of Lead Series
Dr Markku HÄMÄLÄINEN
(GE HEALTHCARE BIO-SCIENCES, Uppsala, Sweden)
15:45OC04 - Pharmacokinetics and the Drug-Target Residence Time Concept
Dr Göran DAHL
(ASTRAZENECA, Mölndal, Sweden)
16:10Coffee Break
16:45OC05 - Bringing Light into Antibody Binding Characteristics in Crude Extracts by Means of FCCS
Dr Frank BECKER
(INTANA BIOSCIENCE GMBH, Planegg, Germany)
17:10PL06 - Can we Use Kinetics and Thermodynamics to Guide Drug Discovery?
Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom)
Chair
Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom)
17:50KN02 - Molecular Mechanism of Action (MMOA) in Drug Discovery
Dr David SWINNEY
(IRND3, Mountain View, United States)
20:00Entertainment (optional & subject to prior registration)
Thursday October 17, 2013
3rd Session - Emerging Technologies
Chair
Dr Matthias FRECH
(MERCK, Darmstadt, Germany)
09:00PL07 - Label-Free, Immobilisation-Free Interaction Studies Using Microscale Thermophoresis
Dr Stefan DUHR
(NANOTEMPER, Munich, Germany)
09:40PL08 - Backscattering Interferometry: An Enabling Drug Development Technology
Dr Darryl BORNHOP
(VANDERBILT UNIVERSITY, Nashville, United States)
10:20OC06 - Detection and Analysis of Proteins with an Electro-Switchable DNA Chip
Dr Ralf STRASSER
(DYNAMIC BIOSENSORS GMBH, Martinsried, Germany)
10:45Coffee Break
11:15OC07 - Binding Rate Constants Measured on Microliter Volume Using On-Chip Temperature Modulation and Fluorescence Lock-In Detection
Dr Charlie GOSSE
(CNRS, Marcoussis, France)
11:40OC08 - CRYO-TEM: The Way to Answer Real Biological Questions through Unraveling the 3D Mechanistics of Protein
Dr Thomas WOHLFARTH
(FEI, Eindhoven/Acht, The Netherlands)
12:05PL09 - Towards Personalised Cancer Medicine with New NMR Tools to Probe Small GTPase Proteins
Dr Chris MARSHALL
(UNIVERSITY OF TORONTO, Toronto, Canada)
12:45Lunch and Networking
14:25Poster Session
15:55Coffee Break
16:25Round-table discussion on hot topics, emerging trends, and new techniques & approaches; sharing of experience and questions from the audience to a panel of experts
Moderator
Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)
17:10Poster Prizes
Chair
Dr Michael HENNIG
(F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland)
17:25KN03 - Combining X-Ray Crystallography and Single-Molecule Methods to Probe Antibiotic Inhibition of Translation
Prof. Jamie CATE
(UNIVERSITY OF CALIFORNIA, Berkeley, United States)
20:00Conference Dinner (optional & subject to prior registration)
Friday October 18, 2013
4th Session - Biophysical Methods for Identifying Hits and Leads
Chair
Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)
09:00PL10 - Application of SPR Biosensors Throughout the Drug Discovery Process
Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)
09:40PL11 - Finding Active Ligands to kRAS Using Solution State NMR
Dr Till MAURER
(GENENTECH, South San Francisco, United States)
10:20Coffee Break
10:50OC09 - Identification and Validation of Small Molecule Inhibitors of G Protein Beta 1 Gamma 2
Dr Preeti BAKRANIA
(MRC TECHNOLOGY, London, United Kingdom)
11:15OC10 - Fragments at UCB: Implementation of Non-Covalent Mass Spectrometry and 19F NMR as Orthogonal Screening Techniques
Dr Hannah MAPLE
(UCB, Slough, United Kingdom)
11:40PL12 - Biophysics in Pharmaceutical Lead Discovery
Dr Johannes OTTL
(NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland)
12:20Closing Remarks and Departure

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys